

BINH DINH PHARMACEUTICAL AND MEDICAL EQUIPMENT JOINT STOCK COMPANY
(Incorporated in the Socialist Republic of Vietnam)

CONSOLIDATED FINANCIAL STATEMENTS
THIRD QUARTER OF 2026



TABLE OF CONTENTS

<u>CONTENTS</u>	<u>PAGE(S)</u>
BOARDS OF DIRECTORS AND MANAGEMENT INTRODUCTION	1
CONSOLIDATED STATEMENT OF FINANCIAL POSITION	2 - 3
CONSOLIDATED INCOME STATEMENT	4
CONSOLIDATED CASH FLOW STATEMENT	5
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS	6 - 26

M.S.D
★

CONSOLIDATED STATEMENT OF FINANCIAL POSITION

As at 30 September 2026

Unit: VND

ASSETS	Code	Notes	As of September 30, 2026	As of December 31, 2025 (Reclassified)
A. CURRENT ASSETS	100		1,574,875,954,101	1,480,040,155,611
I. Cash and cash equivalents	110	4	28,912,767,262	202,783,644,602
1. Cash	111		25,912,767,262	54,783,644,602
2. Cash equivalents	112		3,000,000,000	148,000,000,000
II. Short-term investments	120		519,515,011,024	413,596,450,835
1. Held-for-trading securities	121		1,393,300	1,393,300
2. Short held-to-maturity investments	123	5a	519,513,617,724	413,595,057,535
III. Current accounts receivable	130		520,327,656,264	477,419,351,814
1. Short-term trade receivables	131	6	494,354,057,556	495,347,003,230
2. Short-term advances to suppliers	132	7	82,597,092,503	40,788,245,884
3. Other short-term receivables	135	8	6,109,769,510	4,538,112,905
4. Provision for doubtful debts	136	9	(62,733,263,305)	(63,254,010,205)
IV. Inventories	140		485,790,378,423	366,109,634,763
1. Inventories	141	10	510,406,559,032	397,619,665,024
2. Provision for obsolete inventories	142	10	(24,616,180,609)	(31,510,030,261)
V. Other current assets	160		20,330,141,128	20,131,073,597
1. Short-term deferred expenses	161	11a	12,778,552,871	8,972,511,923
2. Value-added tax deductible	162		6,332,326,229	10,800,145,333
3. Tax and other receivables from the State	163	19	1,219,262,028	358,416,341
B. NON-CURRENT ASSETS	200		1,240,345,092,490	1,116,173,559,655
I. Fixed assets	220		368,136,307,028	354,759,576,495
1. Tangible fixed assets	221	12a	286,413,417,444	272,520,459,520
- Cost	222		889,007,395,132	850,722,766,638
- Accumulated depreciation	223		(602,593,977,688)	(578,202,307,118)
2. Intangible assets	227	12b	81,722,889,584	82,239,116,975
- Cost	228		103,472,327,688	103,210,817,688
- Accumulated amortisation	229		(21,749,438,104)	(20,971,700,713)
II. Long-term biological assets	230	13	990,314,878	950,687,803
1. Long-term harvest crops	237		990,314,878	950,687,803
II. Invested property	240	14	6,163,071,333	-
- Cost	241		6,942,700,361	-
- Accumulated amortisation	242		(779,629,028)	-
III. Long term assets in progress	250		633,950,273,036	539,211,914,318
1. Costs of capital construction in progress	252	15	633,950,273,036	539,211,914,318
IV. Long-term investments	260		174,171,087,133	163,965,069,911
1. Investment in subsidiaries	261		-	-
2. Investments in associates	262		170,799,628,329	162,451,534,940
3. Investment in other entities	263	16	3,513,534,971	3,513,534,971
4. Provision for long term investment devaluation	264	16	(2,000,000,000)	(2,000,000,000)
5. Long – term held-to-maturity investments	265	5b	1,857,923,833	-
V. Other long-term assets	270		56,934,039,082	57,286,311,128
1. Long-term deferred expenses	271	11b	42,819,865,440	41,525,899,197
2. Deferred tax assets	272		14,114,173,642	15,760,411,931
TOTAL ASSETS (280=100+200)	280		2,815,221,046,591	2,596,213,715,266

CONSOLIDATED STATEMENT OF FINANCIAL POSITION (Continued)

As at 30 September 2026

Unit: VND

RESOURCES	Code	Notes	As of September 30, 2026	As of December 31, 2025 (Reclassified)
C. LIABILITIES	300		997,022,928,721	860,234,784,589
I. Current liabilities	310		628,237,774,658	587,673,892,225
1. Short-term Payable to supplier	311	17	184,286,188,449	217,824,029,248
2. Short-term advances from customers	312	18	11,714,573,606	15,454,643,486
3. Dividends payables	313		11,514,277,950	1,600,459,750
4. Taxes and charges payable to the State	314	19	42,415,077,009	53,527,734,518
5. Payables to employees	315		112,142,949,060	93,472,143,498
6. Short-term Costs payable	316	21	12,539,880,099	26,188,049,685
7. Short-term Unrealized revenue	319		163,636,362	-
8. Other short-term payables	320	20	2,366,416,836	8,280,797,971
9. Short-term borrowings and finance lease liabilities	321	22a	154,669,510,715	43,214,775,628
10. Bonus and welfare fund	323	23	96,425,264,572	128,111,258,441
II. Non-current liabilities	330		368,785,154,063	272,560,892,364
1. Long-term loans and finance lease obligations	339	22b	240,358,587,357	132,000,000,000
2. Other long-term provisions	343		8,715,455,167	7,790,562,288
3. Scientific and technological development fund	344	24	119,711,111,539	132,770,330,076
D. OWNERS' EQUITY	400		1,818,198,117,870	1,735,978,930,677
I. Capital	410		1,818,198,117,870	1,735,978,930,677
1. Contributed charter capital/Share capital	411	25	945,293,470,000	945,293,470,000
- Shares with voting rights	411A		945,293,470,000	945,293,470,000
2. Share premium	412		20,921,442,000	20,921,442,000
3. Owners' other capital	414		1,609,359,768	2,242,183,741
4. Shares repurchased from itself	415		(1,952,796,558)	(1,952,796,558)
5. Foreign exchange differences reserve	417		7,894,134,678	8,804,077,510
6. Investment and development fund	418		230,880,981,458	230,880,981,458
7. Undistributed earnings/Accumulated losses	420		613,551,526,524	529,789,572,526
- Undistributed earnings/Accumulated losses up to prior year-end	420A		359,704,710,800	307,961,246,104
- Net profit/loss after tax this period	420B		253,846,815,724	221,828,326,422
TOTAL LIABILITIES AND OWNERS' EQUITY (440=300+400)	440		2,815,221,046,591	2,596,213,715,266

Le Thi Kieu My
Preparer

Do Huy Phuong
Chief Accountant

Pham Thi Thanh Huong
General Director
October 26, 2026

CONSOLIDATED INCOME STATEMENT

THIRD QUARTER OF 2026

As at 30 september 2026

Unit: VND

Numerical order	Items	Code	Notes	Third quarter of 2026	Third quarter of 2025	Accumulated nine months of 2026	Accumulated nine months of 2025
1.	Gross revenue from goods sold and service rendered	01	27	471,953,058,980	457,036,601,492	1,410,027,885,322	1,409,576,627,478
2.	Deductions	02	27	11,866,963,100	17,338,229,305	30,188,493,342	54,296,185,249
3.	Net revenue from goods sold and service rendered (10=01-02)	10	28	460,086,095,880	439,698,372,187	1,379,839,391,980	1,355,280,442,229
4.	Cost of sales	11	29	251,269,982,657	252,404,294,273	741,689,619,547	697,363,708,153
5.	Gross profit from goods sold and service rendered (20=10-11)	20		208,816,113,223	187,294,077,914	638,149,772,433	657,916,734,076
6.	Financial income	22	30	9,869,923,779	9,088,076,486	27,832,924,607	18,296,240,673
7.	Financial expenses	23	31	3,038,410,178	4,090,480,901	11,280,630,233	10,786,960,734
	- In which: Interest expense	24	31	579,493,949	1,339,973,239	2,081,608,735	2,844,596,315
8.	Selling expenses	25	32	96,946,569,507	88,096,365,357	302,227,403,034	313,830,362,879
9.	General and administration expenses	26	33	23,450,198,094	23,571,257,861	71,673,776,189	77,822,880,183
10.	Share of net profit from joint-ventures, associates	27		10,266,702,188	(8,441,185,109)	28,663,657,967	3,149,956,573
11.	Operating profit/(loss) (30=20+21+(22-23)+24-(25+26))	30		105,517,561,411	72,182,865,172	309,464,545,551	276,922,727,526
12.	Other income	31		32,755,090	110,901,386	126,513,095	315,927,542
13.	Other expenses	32		4,212,330,769	825,721,183	4,897,610,037	3,124,197,569
14.	Other profit/ (loss) (40=31-32)	40		(4,179,575,679)	(714,819,797)	(4,771,096,942)	(2,808,270,027)
15.	Accounting profit/ (loss) before tax (50=30+40)	50		101,337,985,732	71,468,045,375	304,693,448,609	274,114,457,499
16.	Current corporate income tax expense	51	34	16,145,947,682	11,910,845,417	49,136,958,425	43,362,755,693
17.	Deferred income tax income/ (expense)	52	34	751,711,246	(351,835,610)	1,646,238,290	(503,089,344)
18.	Net profit/ (loss) after tax (60=50-51-52)	60		84,440,326,804	59,909,035,568	253,910,251,894	231,254,791,150

Le Thi Kieu My
Preparer

Do Huy Phuong
Chief Accountant

Pham Thi Thanh Huong
General Director
October 26, 2026


CONSOLIDATED CASH FLOW STATEMENT
For the nine-month period ended September 30, 2026

Unit: VND

Code	Items	Accumulated nine months of 2026	Accumulated nine months of 2025
I.	CASH FLOWS FROM OPERATING ACTIVITIES		
1.	<i>Profit/(loss) before tax</i>	304,693,448,609	274,114,457,500
	<i>Adjustments for:</i>		
2.	Depreciation of tangible fixed assets and investment properties and amortisation of intangible fixed assets	29,767,247,137	38,349,338,641
3.	Provisions/(reversal of provision)	(6,489,703,673)	(7,087,607,129)
4.	Foreign exchange (gains)/losses arising from revaluation of monetary accounts denominated in monetary currency	101,504,250	(171,678,337)
5.	(Profits)/losses from investing activities	(55,161,115,362)	(16,721,897,520)
6.	Interest expenses	2,081,608,735	2,844,596,315
7.	Other adjustments	-	-
8.	Operating profit/(loss) before changes in working capital	274,992,989,696	291,327,209,470
9.	(Increase)/decrease in receivables	(4,458,276,809)	3,954,894,968
10.	(Increase)/decrease in inventories	(112,786,894,008)	129,212,058,821
11.	Increase/(decrease) in payables	(75,111,462,425)	32,084,053,629
12.	(Increase)/decrease in prepaid expenses	(5,100,007,191)	458,148,331
14.	Interest paid	(2,107,721,735)	(2,945,089,315)
15.	Corporate income tax paid	(62,465,383,416)	(31,823,079,112)
16.	Other cash inflows from operating activities	14,040,000	1,248,815,372
17.	Other cash outflows for operating activities	(22,287,460,055)	(21,823,163,819)
20.	Net cash from/(used in) operating activities	(9,310,175,942)	401,693,848,345
II.	CASH FLOWS FROM INVESTING ACTIVITIES		
21.	Purchase and construction of fixed assets	(139,333,352,006)	(273,038,208,185)
23.	Bank term deposits	(284,776,484,022)	(206,409,222,001)
24.	Collection of bank term deposits	177,000,000,000	32,919,765,300
27.	Interest and dividends received	41,821,497,926	12,192,735,602
30.	Net cash from/(used in) investing activities	(205,288,338,102)	(434,334,929,284)
III.	CASH FLOWS FROM FINANCING ACTIVITIES		
31.	Capital contribution and issuance of shares	-	9,355,000,000
33.	Drawdown of borrowings	365,824,992,025	168,970,230,767
34.	Repayment of borrowings	(146,011,669,581)	(54,364,202,920)
36.	Dividends paid/Profit distributed	(179,064,705,800)	(185,523,560,475)
40.	Net cash flows from/(used in) financing activities	40,748,616,644	(61,562,532,628)
50.	Net increase/(decrease) in cash for the year	(173,849,897,400)	(94,203,613,567)
60.	Cash [and cash equivalents] at beginning of year	202,783,644,602	314,198,731,825
61.	Impact of exchange rate fluctuation	(20,979,940)	(4,281,177)
70.	Cash [and cash equivalents] at end of year	28,912,767,262	219,990,837,081


Le Thi Kieu My
Preparer


Do Huy Phuong
Chief Accountant


Pham Thi Thanh Huong
General Director
October 26, 2026

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

(These notes are an integral part of and should be read in conjunction with the accompanying consolidated financial statements)

1. CORPORATE INFORMATION

Binh Dinh Pharmaceutical and Medical Equipment Joint Stock Company (BIDIPHAR) ("the Company") was formerly known as Binh Dinh Pharmaceutical and Medical Equipment Company which was transformed from a state-owned enterprise into a one-member limited liability company owned by People's Committee of Binh Dinh Province in accordance with the Decision No. 264/QĐ-UBND on 23 June 2010 and the first Enterprise Registration Certificate ("ERC") No. 4100259564 issued by Department of Planning and Investment ("DPI") of Binh Dinh Province on 1 September 2010. Since March 2014, the Company has changed its legal ownership form from one-member limited liability company to joint stock company according to the second amended ERC No. 4100259564 issued by the DPI of Binh Dinh Province on 1 March 2014 and 14th amended ERC issued by the Department of Enterprise and Collective Economy under the Department of Finance of Gia Lai Province on 11 September 2025.

The Company's shares were listed on the Ho Chi Minh City Stock Exchange ("HOSE") with trading code as DBD in accordance with License No. 185/QĐ-SGDHCM issued by the HOSE on 24 May 2018.

The principal activities of the Group are manufacturing and trading in pharmaceutical products and medical equipment.

The Group's normal course of business cycle is 12 months.

The Company's registered head office is located at 498 Nguyen Thai Hoc Street, Quy Nhon Nam Ward, Gia Lai Province, Vietnam. In addition, the Company also has fifteen (15) branches located at other province/cities within Vietnam.

The number of the Group's employees as at 30 September 2026 was 1,498 employees.

Corporate structure

As at 30 September 2026, the Group's corporate structure included two (2) subsidiaries and an associate. Details are as follows:

Name		Head office	Business activities	30 September 2026 and 31 December 2025	
				Ownership (%)	Voting rights (%)
Subsidiaries					
(1)	Bidiphar Trading Company Limited	Gia Lai Province	Wholesale and retail sale of medicines, medicinal herbs, medical equipment	100.00	100.00
(2)	Bidiphar Organic Medicine Limited Company	Gia Lai Province	Production of medicines, medicinal chemicals and medicinal herbs	100.00	100.00
Associate					
(1)	Bidiphar Rubber Joint Stock Company	Gia Lai Province	Planting, mining, processing and trading rubber latex	33.58	33.58

2. BASIS OF PREPARATION

2.1 Accounting standards and system

This consolidated financial statements have been prepared in accordance with the Vietnamese Accounting Standards (VAS), the Vietnamese Enterprise Accounting System, and relevant prevailing legal regulations governing the preparation and presentation of consolidated financial statements. Specifically:

On 27 October 2025, the Ministry of Finance issued Circular No. 99/2025/TT-BTC providing guidance on the Vietnamese Accounting System for Enterprises ("Circular 99"). Circular 99 replaces the previous guidance on Vietnamese Accounting System for Enterprises under Circular No. 200/2014/TT-BTC dated 22 December 2014 ("Circular 200") and other circulars amending and supplementing Circular 200. Circular 99 is effective from 1 January 2026 and applicable for annual accounting periods beginning on or after 1 January 2026.

On 20 April 2026, the Ministry of Finance issued Circular No. 43/2026/TT-BTC ("Circular 43"), which amends and supplements certain articles of Circular No. 202/2014/TT-BTC dated 22 December 2014 on the guidance for preparation and presentation of consolidated financial statements. Circular 43 is effective from the date issuance and applicable to the preparation and presentation of consolidated financial statements for fiscal years beginning on or after 1 January 2026.

The Group has adopted the applicable requirements of Circular 99 and Circular 43 effective from 1 January 2026 on a prospective basis, with reclassification of certain corresponding items, unless Circular 99 and Circular 43 specifically stipulates otherwise.

The accompanying consolidated financial statements, including their utilization are not designed for those who are not informed about Vietnam's accounting principles, procedures and practices and furthermore are not intended to present the consolidated financial position and consolidated results of operations and consolidated cash flows in accordance with accounting principles and practices generally accepted in countries other than Vietnam.

2.2 Applied accounting documentation system

The Group's applied accounting documentation system is the Computerised based.

2.3 Accounting Period

The Group's fiscal year applicable for the preparation of its consolidated financial statements starts on 1 January and ends on 31 December.

The consolidated interim financial statements are prepared for the nine-month period ended 30 september 2026.

2.4 Accounting currency

The consolidated financial statements are prepared in VND which is also the Group's accounting currency.

2.5 Basic of consolidation

The consolidated financial statements comprise the separate financial statements of the Company and its subsidiaries for the Third quarter ended 30 September 2026.

Subsidiaries are fully consolidated from the date of acquisition, being the date on which the Group obtains control, and continued to be consolidated until the date that such control ceases.

The financial statements of the subsidiary are prepared for the same reporting period as the parent company, using consistent accounting policies.

All intra-company balances, income and expenses and unrealized gains or losses resulted from intra-company transactions are eliminated in full.

Non-controlling interests represent the portion of profit or loss and net assets not held by the Group and are presented separately in the consolidated income statement and within equity in the consolidated statement of financial position.

Impact of change in the ownership interest of a subsidiary, without a loss of control, is recorded in undistributed earnings.

3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

3.1 Cash and cash equivalents

Cash and cash equivalents comprise cash on hand, cash in banks and short-term, highly liquid investments with an original maturity of less than three months that are readily convertible into known amounts of cash and that are subject to an insignificant risk of changes in value.

3.2 Inventories

Inventories are measured at their historical costs. The cost of inventories comprises costs of purchase, costs of conversion (including raw materials, direct labor cost, other directly related cost, manufacturing general overheads allocated based on the normal operating capacity) incurred in bringing the inventories to their present location and condition.

In case the net realizable value is lower than the original price, it must be calculated according to the net realizable value. Net realisable value represents the estimated selling price in the ordinary course of business less the estimated costs to complete and the estimated costs necessary to make the sale.

The perpetual method is used to record inventories, which are valued as follows:

- | | |
|--|---|
| Raw materials, tool and supplies and merchandise | - actual cost on a weighted average basis. |
| Work-in-process and finished goods | - cost of finished goods and work-in-process on a weighted average basis. |

Provision for obsolete inventories

An inventory provision is created for the estimated loss arising due to the impairment of value (through diminution, damage, obsolescence, etc.) of raw materials, finished goods, merchandise and other inventories owned by the Group, based on appropriate evidence of impairment available at the balance sheet date.

Increases or decreases to the provision balance are recorded into the cost of goods sold account in the consolidated income statement. When inventories are expired, obsolescence, damage or become useless, the difference between the provision previously made and the historical cost of inventories are included in the consolidated income statement.

3.3 Receivables

Receivables are presented in the consolidated statement of financial position at the carrying amounts due from customers and other debtors, after the provision for doubtful receivables.

The provision for doubtful receivables represents amounts of outstanding receivables at the balance sheet date which are doubtful of being recovered. Increases or decreases to the provision balance are recorded as general and administrative expense in the consolidated income statement. When bad debts are determined as unrecoverable and accountant written off those bad debts, the differences between the provision for doubtful receivables previously made and historical cost of receivables are included in the consolidated income statement.

Trade and other receivables that are not past due but are assessed as unlikely to be collected based on available evidence at the end of the accounting period shall have an allowance provided on case-by-case basis. The allowance for overdue trade and other receivables is calculated based on aging analysis and specific provisioning rates as below:

	Allowance Percentage
Past due 6 months – 1 year	30%
Past due 1 – 2 years	50%
Past due 2 – 3 years	70%
Past due more than 3 years	100%

Prior to January 1, 2026, interest receivables from held-to-maturity investments were recognized under other receivables.

3.4 Fixed assets

Tangible fixed assets

Tangible fixed assets are stated at cost less accumulated depreciation.

The cost of a tangible fixed asset comprises its purchase price and any directly attributable costs of bringing the tangible fixed asset to working condition for its intended use. Expenditures for additions, improvements and renewals are added to the carrying amount of the assets and expenditures for maintenance and repairs are charged to the consolidated income statement as incurred.

When tangible fixed assets are sold or retired, any gain or loss resulting from their disposal (the difference between the net disposal proceeds and the carrying amount) is included in the consolidated income statement.

Intangible fixed assets

Intangible fixed assets are stated at cost less accumulated amortization.

The cost of an intangible fixed asset comprises its purchase price and any directly attributable costs of preparing the intangible fixed asset for its intended use. Expenditures for additions, improvements are added to the carrying amount of the assets and other expenditures are charged to the consolidated income statement as incurred.

When intangible fixed assets are sold or retired, any gain or loss resulting from their disposal (the difference between the net disposal proceeds and the carrying amount) is included in the consolidated income statement.

Land used rights

Land use rights are recorded as intangible fixed assets representing the value of the rights to use the lands acquired by the Group. The advance payment for land rental, of which the land lease contracts, and Land use rights certificate being issued, are recorded as intangible fixed asset according to Circular No. 45/2013/TT-BTC issued by the Ministry of Finance on 25 April 2013 guiding the management, use and depreciation of fixed assets ("Circular 45").

The useful life of land use rights are assessed as either definite or indefinite. Accordingly, the land use rights with definite useful life representing the land lease are amortized over the lease term while the land use rights with indefinite useful lives is not amortized.

3.5 Biological assets

Biological assets comprise plants producing one-time products.

Biological assets are stated at cost less allowance for impairment loss. Initial cost of a biological asset comprises its purchase price and any directly attributable costs of raising, cultivating the asset until it reaches maturity stage or harvest point. An allowance is made for biological assets if there is evidence that the asset is impaired, or its net realisable value falls below its carrying amount.

3.6 Depreciation and amortization

Depreciation of tangible fixed assets and amortization of intangible fixed assets are calculated on a straight-line basis over the estimated useful life of each asset as follows:

Buildings and structures	4 - 43 years
--------------------------	--------------

Machinery and equipment	4 - 12 years
Means of transportation	4 - 10 years
Office equipment	4 - 10 years
Computer software	4 - 10 years
Land use rights	50 years

3.7 Construction in progress

Construction in progress represents fixed assets under construction and is stated at cost. This includes costs of construction, installation of equipment and other direct costs. Construction in progress is not depreciated until such time as the relevant assets are completed and put into operation.

3.8 Borrowing costs

Borrowing costs consist of interest and other costs that the Group incurs in connection with the borrowing of funds.

3.9 Leased assets

The determination of whether an arrangement is, or contains a lease is based on the substance of the arrangement at inception date and requires an assessment of whether the fulfilment of the arrangement is dependent on the use of a specific asset and the arrangement conveys a right to use the asset.

A lease is classified as a finance lease whenever the terms of the lease transfer substantially all the risks and rewards of ownership of the asset to the lessee. All other leases are classified as operating leases.

Where the Group is the lessee

Rentals under operating leases are charged to the consolidated income statement on a straight-line basis over the term of the lease.

3.10 Deferred expenses

Deferred expenses are reported as short-term or long-term deferred expenses on the consolidated statement of financial position and amortized over the period for which the amounts are paid or the period in which economic benefits are generated in relation to these expenses.

3.11 Accrual for severance pay

The severance pay to employee is accrued at the end of each reporting year for employees who have been worked for more than 12 months at the Group. The accrued amount is calculated at the rate of one-half of the average monthly salary for each year of service qualified for severance pay in accordance with the Labour Code and related implementing guidance. The average monthly salary used in this calculation will be revised at the end of each reporting period following the average monthly salary of the 6-month period up to the reporting date. Any increase or decrease to the accrued amount other than actual payment to employee will be taken to the consolidated income statement.

This accrued severance pay is used to settle the termination allowance to be paid to employee upon termination of their labour contract following Article 46 of the Labour Code.

3.12 Business combinations

Business combinations are accounted for using the purchase method. The cost of a business combination is measured as the fair value of assets given, equity instruments issued and liabilities incurred or assumed at the date of exchange plus any costs directly attributable to the business combination. Identifiable assets and liabilities and contingent liabilities assumed in a business combination are measured initially at fair values at the date of business combination.

3.13 Investments

Investment in an associate

The Group's investment in its associate is accounted for using the equity method of accounting. An associate is an entity in which the Group has significant influence that is neither subsidiaries nor joint ventures. The Group generally deems they have significant influence if they have over 20% of the voting rights.

Under the equity method, the investment is carried in the consolidated statement of financial position at cost plus post-acquisition changes in the Group's share of net assets of the associates. Goodwill arising on acquisition of the associate is included in the carrying amount of the investment. Goodwill is not amortized and subject to annual review for impairment. The consolidated income statement reflects the share of the post-acquisition results of operation of the associate.

The share of post-acquisition profit (loss) of the associate is presented on face of the consolidated income statement and its share of post-acquisition movements in reserves is recognized in reserves. The cumulative post-acquisition movements are adjusted against the carrying amount of the investment. Dividend/profit sharing receivable from associate reduces the carrying amount of the investment.

The financial statements of the associate are prepared for the same reporting period and use the same accounting policies as the Group. Where necessary, adjustments are made to bring the accounting policies in line with those of the Group.

Held-for-trading securities and investments in other entities

Held-for-trading securities and investments in other entities are stated at their acquisition costs.

Provision of the investments

Provision for diminution in value of the investment is made when there are reliable evidences of the diminution in value of those investments at the balance sheet date.

Increases or decreases to the provision balance are recorded as finance expense in the consolidated income statement.

Held-to-maturity investments

Held-to-maturity investments are stated at their acquisition costs. After initial recognition, held-to-maturity investments are measured at recoverable amount. Any impairment loss incurred is recognized as expense in the consolidated financial statements and deducted against the value of such investments.

Effective from 1 January 2026, accrued interest income receivables on held-to-maturity investments are recognised under the related held-to-maturity investments account in the consolidated statement of financial position. Prior to 1 January 2026, accrued interest income receivables were recognised under other receivables.

3.14 Payables and accruals

Payables and accruals are recognized for amounts to be paid in the future for goods and services received, whether or not billed to the Group.

3.15 Foreign currency transactions

Transactions arising in currencies other than the currency used in the Company's accounting in VND are recorded at the actual transaction exchange rate on the transaction date, which is the average buying and selling transfer rate of the commercial bank that the Company regularly transacts with or the commercial bank that the Company is currently transacting with.

At the end of the accounting period, the Company re-evaluates the exchange rates of foreign currency-denominated monetary items according to the principle:

- Monetary items with foreign currency denominated principal are revalued at the average buying and selling transfer rates of the commercial bank where the Company regularly transacts.
- Separately, the balance of non-term deposits in foreign currency is re-evaluated according to the average transfer buying and selling rate of the commercial bank where the Company has the deposit account.

All foreign exchange differences incurred are taken to the consolidated income statement.

3.16 Treasury shares

Own equity instruments which are reacquired (treasury shares) are recognized at cost and deducted from equity. No gain or loss is recognized in profit or loss upon purchase, sale, re-issue or cancellation of the Group's own equity instruments.

3.17 Appropriation of net profits

Net profit after tax (excluding negative goodwill arising from a bargain purchase) is available for appropriation to shareholders after approval in the annual general meeting, and after making appropriation to reserve funds in accordance with the Company's Charter and Vietnam's regulatory requirements.

The Group maintains the following reserve funds which are appropriated from the Group's net profit as proposed by the Board of Directors and subject to approval by shareholders at the annual general meeting:

Investment and development fund

This fund is set aside for use in the Group's expansion of its operation or of in-depth investments.

Bonus and welfare fund

This fund is comprised of bonus, welfare fund for employees and bonus fund for the management, which is set aside for the purpose of pecuniary rewarding and encouraging, common benefits and improvement of the employees' benefits. This fund is presented as a liability on the consolidated statement of financial position.

Dividends

Dividends proposed by the Group's Board of Directors are classified as an allocation of undistributed earnings within the equity section of the consolidated statement of financial position, until they have been approved by the Group's shareholders at the Annual General Meeting. When these dividends have been approved by the shareholders and declared, they are recognized as a liability in the consolidated statement of financial position.

Effective from 1 January 2026, dividends payable are recognised under dividends payable account in the consolidated statement of financial position.

3.18 Earnings per share

Basic earnings per share amount is computed by dividing net profit attributable to ordinary equity holders of the Group (after adjusting for the bonus and welfare fund) by the weighted average number of ordinary shares outstanding during the period.

Diluted earnings per share amounts are calculated by dividing the net profit after tax attributable to ordinary equity holders of the Group by the weighted average number of ordinary shares outstanding during the period plus the weighted average number of ordinary shares that would be issued on conversion of all the dilutive potential ordinary shares into ordinary shares.

3.19 Revenue recognition

Revenue is recognized to the extent that it is probable that the economic benefits will flow to the Group and the revenue can be reliably measured. Revenue is measured at the fair value of the consideration received or receivable, excluding trade discount, rebate and sales return. The following specific recognition criteria must also be met before revenue is recognized:

Sale of goods

Revenue is recognized when the significant risks and rewards of ownership of the goods have passed to the buyer, usually upon the delivery of the goods.

Rendering of services

Revenue is recognized when the services have been performed and completed.

Interest income

Interest is recognized on an accrual basis based on the time and actual interest rate for each period.

Dividend and profit distribution income

Dividend and profit distribution income are recognized when Group is entitled to receive dividends or when the Group are entitled to receive profits from its capital contributions.

3.20 Taxation

Current income tax

Current income tax assets and liabilities for the current and prior periods are measured at the amount expected to be paid to or recovered from the taxation authorities. The tax rates and tax laws used to compute the amount are those that are enacted as at the balance sheet date.

Current income tax is charged or credited to the consolidated income statement, except when it relates to items recognized directly to equity, in which case the current deferred income tax is also dealt with in equity.

Current income tax assets and liabilities are offset when there is a legally enforceable right for the Group to set off current income tax assets against current income tax liabilities and when the Group intend to settle its current income tax assets and liabilities on a net basis.

Deferred tax

Deferred tax is provided using the liability method on temporary differences at the balance sheet date between the tax base of assets and liabilities and their carrying amount for financial reporting purpose.

Deferred tax liabilities are recognized for all taxable temporary differences. Deferred tax assets are recognized for all deductible temporary differences, carried forward unused tax credit and unused tax losses, to the extent that it is probable that taxable profits will be available against which deductible temporary differences, carried forward unused tax credit and unused tax losses can be utilized.

The carrying amount of deferred tax assets is reviewed at each balance sheet date and reduced to the extent that it is no longer probable that sufficient taxable profit will be available to allow all or part of the deferred tax asset to be utilized. Previously unrecognized deferred tax assets are re-assessed at each balance sheet date and are recognized to the extent that it has become probable that future taxable profit will allow the deferred tax assets to be recovered.

Deferred tax assets and liabilities are measured at the tax rates that are expected to apply in the year when the asset is realized, or the liability is settled based on tax rates and tax laws that have been enacted at the balance sheet date.

Deferred tax is charged or credited to the consolidated income statement, except when it relates to items recognized directly to equity, in which case the deferred tax is also dealt with in the equity account.

Deferred tax assets and liabilities are offset when there is a legally enforceable right for the Group to offset current tax assets against current tax liabilities and when they relate to income taxes levied by the same taxation authority on the same taxable entity or when the Group intends either to settle current tax liabilities and assets on a net basis or to realize the assets and settle the liabilities simultaneously, in each future year in which significant amounts of deferred tax liabilities or assets are expected to be settled or recovered.

3.21 Segment reporting

A segment is a component determined separately by the Group which is engaged in providing products or related services (business segment) or providing products or services in a particular economic environment (geographical segment), that is subject to risks and returns that are different from those of other segments. As the Company's revenue and profit are derived mainly from manufacturing and trading pharmaceutical products in Vietnam while other sources of revenue are not material as a whole, management accordingly believes that the Group operates in a sole business segment of manufacturing and trading pharmaceutical products within a single geographical segment. Therefore, no further segmental information is required to be presented.

3.22 Related parties

Parties are considered to be related parties of the Group if one party has the ability to control the other party or exercise significant influence over the other party in making financial and operating decisions, or when the Group and other party are under common control or under common significant influence. Related parties can be enterprise or individual, including close members of the family of any such individual.

4. CASH AND CASH EQUIVALENTS:

	As of September 30, 2026	As of December 31, 2025
	VND	VND
Cash on hand	615,292,954	1,545,696,148
Cash in banks	25,297,474,308	53,237,948,454
Cash equivalent (*)	3,000,000,000	148,000,000,000
	28,912,767,262	202,783,644,602

(*) Cash equivalents represent term deposits with original term of less than or equal to 3 months at commercial banks.

5. HELD-TO-MATURITY INVESTMENTS :

	As of September 30, 2026	As of December 31, 2025
	VND	VND (Reclassified)
a. Short-term Investments held to maturity (*)		
Investment Principal	509,442,143,835	409,200,000,000
Accrued Interest Receivable	7,571,473,890	4,395,057,535
	519,513,617,724	413,595,057,535
b. Long-term Investments held to maturity (*)		
Investment Principal	1,824,728,767	-
Accrued Interest Receivable	33,195,066	-
	1,857,923,833	-

(*) Held-to-maturity investments comprise term deposits placed with banks that have original maturities of more than three months from the deposit date. These investments are classified as short-term when their remaining maturities are not more than 12 months and as long-term when their remaining maturities exceed 12 months from the end of the accounting period. Interest income is earned at the applicable rates for term deposits offered by the respective banks.

6. SHORT-TERM TRADE RECEIVABLES:

	As of September 30, 2026	As of December 31, 2025
	VND	VND
K Hospital Hanoi	19,588,415,490	17,831,669,100
Gia Lai Central General Hospital	14,113,977,701	15,186,298,375
Dong Nam Technical Investment Company	45,131,856,249	45,131,856,249
Kien Tao Co., Ltd	11,539,449,445	11,539,449,445
Others	403,980,358,671	405,657,730,061
	494,354,057,556	495,347,003,230

7. SHORT-TERM ADVANCES TO SUPPLIERS:

	As of September 30, 2026	As of December 31, 2025
	VND	VND
Tuan Thang Limited Liability Company	5,580,000,000	-
Nam Viet Technology Company	5,286,113,136	2,329,100,568
Viet Son Engineering Company	9,054,362,074	4,434,147,686
Khai Dat Construction Design Joint Stock Company	11,690,796,341	-
Others	50,985,820,952	34,024,997,630
	82,597,092,503	40,788,245,884

8. OTHER SHORT-TERM RECEIVABLES:

	As of September 30, 2026	As of December 31, 2025
	VND	VND (Reclassified)
Advance to employees	2,442,781,122	349,414,190
Land Clearance Compensation Receivable - Hoai Nhon	740,189,813	740,189,813
Others	2,926,798,575	3,448,508,902
	6,109,769,510	4,538,112,905

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)

9. ALLOWANCE FOR DOUBTFUL DEBTS:

	As of September 30, 2026			Beginning balance		
	Cost	Allowance	Recoverable amount	Cost	Allowance	Recoverable amount
	VND	VND	VND	VND	VND	VND
<i>Accounts receivable from customers</i>						
Dong Nam Technical Development and Investment Company Limited	45,131,856,249	(45,131,856,249)	-	45,131,856,249	(45,131,856,249)	-
Kien Tao Company Limited	11,539,449,445	(11,539,449,445)	-	11,560,756,445	(11,560,756,445)	-
Other customers	4,357,772,438	(2,326,327,606)	2,031,444,832	5,255,292,623	(2,932,060,272)	2,323,232,351
	<u>61,029,078,132</u>	<u>(58,997,633,300)</u>	<u>2,031,444,832</u>	<u>61,947,905,317</u>	<u>(59,624,672,966)</u>	<u>2,323,232,351</u>
<i>Prepayment to suppliers</i>	1,470,549,538	(1,453,768,538)	16,781,000	1,474,299,538	(1,347,475,772)	126,823,766
<i>Other receivables</i>	2,281,861,467	(2,281,861,467)	-	2,281,861,467	(2,281,861,467)	-
	<u>64,781,489,137</u>	<u>(62,733,263,305)</u>	<u>2,048,225,832</u>	<u>65,704,066,322</u>	<u>(63,254,010,205)</u>	<u>2,450,056,117</u>

10. INVENTORIES:

	As of September 30, 2026		Beginning balance	
	Cost	Provision	Cost	Provision
	VND	VND	VND	VND
Goods in transit	-	-	21,005,148,055	-
Raw materials	312,441,305,217	(24,036,949,238)	232,926,577,547	(30,381,868,122)
Tools and equipment	2,040,756,365	-	1,470,071,105	-
Work in progress	11,303,833,528	-	27,386,165,637	-
Finished goods	178,161,650,613	(279,166,293)	110,681,721,156	(949,155,812)
Merchandise goods	6,459,013,309	(300,065,078)	4,149,981,524	(179,006,327)
	510,406,559,032	(24,616,180,609)	397,619,665,024	(31,510,030,261)

Movements of the allowance for inventories during the period were as follows:

	Nine-month period ended	
	30/9/2026	30/9/2025
	VND	VND
Opening balance	31,510,030,261	26,955,944,409
Increase in allowance during the period	1,085,942,969	46,245,567
Allowance reversed during the period	(7,979,792,621)	(3,335,782,235)
Closing balance	24,616,180,609	23,666,407,741

11. DEFERRED EXPENSES:

	As of September 30, 2026	As of December 31, 2025
	VND	VND
a, Short term		
Tools and supplies	2,510,301,182	3,175,150,107
Maintenance and repair	3,733,170,316	3,050,224,733
Office rental, land rental	207,800,000	401,900,000
Others	6,327,281,373	2,345,237,083
	12,778,552,871	8,972,511,923
b, Long term		
Tools and supplies	2,391,390,894	2,758,811,095
Maintenance and repair	9,735,682,339	7,681,864,024
Office rental, land rental	28,845,606,396	29,374,180,800
Others	1,847,185,811	1,711,043,278
	42,819,865,440	41,525,899,197

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)

12. FIXED ASSETS:

a. *Tangible fixed assets*

	Buildings and structure	Machinery and equipment	Means of transportation	Office equipment	Bearer Plants	Total
	VND	VND	VND	VND	VND	VND
Cost:						
As of January 01, 2026	234,506,001,444	539,907,206,653	52,098,421,330	23,144,792,657	1,066,344,554	850,722,766,638
Construction in progress completed	100,665,148	39,246,913,890	3,544,907,482	-	-	42,892,486,520
Newly purchases	507,949,593	2,830,444,473	5,546,899,386	-	-	8,885,293,452
Reclassification to investment property	(6,942,700,361)	-	-	-	-	(6,942,700,361)
Disposal	(1,137,000,000)	(5,280,796,572)	-	(132,654,545)	-	(6,550,451,117)
As of September 30, 2026	227,034,915,824	576,703,768,444	61,190,228,198	23,012,138,112	1,066,344,554	889,007,395,132
Accumulated depreciation:						
As of January 01, 2026	154,323,014,593	363,203,754,437	42,117,875,601	18,024,490,209	533,172,278	578,202,307,118
Depreciation for the period	4,354,027,485	24,503,346,830	1,925,957,911	805,125,420	133,293,069	31,721,750,715
Reclassification to investment property	(779,629,028)	-	-	-	-	(779,629,028)
Disposal	(1,137,000,000)	(5,280,796,572)	-	(132,654,545)	-	(6,550,451,117)
As of September 30, 2026	156,760,413,050	382,426,304,695	44,043,833,512	18,696,961,084	666,465,347	602,593,977,688
Net carrying amount:						
As of January 01, 2026	80,182,986,851	176,703,452,216	9,980,545,729	5,120,302,448	533,172,276	272,520,459,520
As of September 30, 2026	70,274,502,774	194,277,463,749	17,146,394,686	4,315,177,028	399,879,207	286,413,417,444

b. Intangible assets

	Land use rights	Computer software	Total
	VND	VND	VND
Cost:			
As of January 01, 2026	82,343,592,946	20,867,224,742	103,210,817,688
Newly purchases	-	-	-
Construction in progress completed	-	-	-
Disposal	-	-	-
As of September 30, 2026	82,343,592,946	20,867,224,742	103,210,817,688
Accumulated depreciation:			
As of January 01, 2026	3,159,172,294	17,812,528,419	20,971,700,713
Depreciation for the period	170,672,910	607,064,481	777,737,391
Disposal	-	-	-
As of September 30, 2026	3,329,845,204	18,419,592,900	21,749,438,104
Net carrying amount:			
As of January 01, 2026	79,184,420,652	3,054,696,323	82,239,116,975
As of September 30, 2026	79,013,747,742	2,709,141,842	81,722,889,584

13. BIOLOGICAL ASSETS – LONG -TERM:

	As of September 30, 2026	As of December 31, 2025
	VND	VND (Reclassified)
Seasonal crops or plants producing one-time products – long-term		
Hybrid Acacia	242,075,885	242,075,885
Rehmannia glutinosa	205,822,442	205,822,442
Morinda Root	167,198,165	167,198,165
Fo-Ti	165,041,205	165,041,205
Solanum procumbens	136,757,828	-
Others	73,419,353	170,550,106
	990,314,878	950,687,803

14. INVESTMENT PROPERTY:

Investment property held to earn rental	Buildings and structures
	VND
Cost	
Opening balance	-
Reclassification from tangible fixed assets	6,942,700,361
Closing balance	6,942,700,361
Accumulated depreciation	
Opening balance	-
Reclassification from tangible fixed assets	779,629,028
Closing balance	779,629,028
Net book value	
Opening balance	-
Closing balance	6,163,071,333

15. COSTS CAPITAL CONSTRUCTION IN PROGRESS:

	As of September 30, 2026	As of December 31, 2025
	VND	VND
Hi-tech pharmaceutical factory (Nhon Hoi)	614,589,713,930	503,589,550,775
Powder injection line	-	23,496,972,309
Others	19,360,559,106	12,125,391,234
	633,950,273,036	539,211,914,318

16. EQUITY INVESTMENT IN OTHER ENTITIES:

	Ownership	Number of shares	As of September 30, 2026 and as of January 01, 2026	
	Tỷ lệ phần sở hữu	Số lượng cổ phần	Cost	Provision
	%		VND	VND
Nghe An Pharmaceutical Medical Material and Equipment JSC	3.4	205,710	1,513,534,971	-
Thien Phuc JSC	10.0	200,000	2,000,000,000	2,000,000,000
			3,513,534,971	2,000,000,000

17. SHORT-TERM TRADE PAYABLES:

	As of September 30, 2026	As of December 31, 2025
	VND	VND
Bach Khoa Limited Liability Company	8,871,784,504	19,264,779,810
Tofflon Science	33,194,724,150	33,458,881,599
Truking Technology Limited	13,465,299,568	13,001,682,260
Cheiron Pharma	14,677,426,637	6,309,429,905
Others	114,076,953,590	145,789,255,674
	184,286,188,449	217,824,029,248

18. SHORT-TERM ADVANCES FROM CUSTOMERS:

	As of September 30, 2026	As of December 31, 2025
	VND	VND
VP-Pharma Pharmaceutical JSC	1,488,856,833	5,940,546,470
Sundial Pharma JSC	2,197,903,274	1,457,124,271
Rexton JSC	1,362,160,950	1,097,788,200
T&T Equipment Joint Stock Company	1,039,500,000	2,425,500,000
Others	5,626,152,549	4,533,684,545
	11,714,573,606	15,454,643,486

19. TAXES AND OTHER RECEIVABLES FROM/PAYABLES TO THE STATE BUDGET:

	As of January 01, 2026	To be submitted in nine months of 2026	Submitted in nine months of 2026	As of september30, 2026
	VND	VND	VND	VND
Value-added tax ("VAT")	405,646,343	2,067,495,665	2,153,743,614	319,398,394
+Payable	405,646,343	2,067,495,665	2,153,743,614	319,398,394
+Receivable	-	-	-	-
VAT on imported goods	(297,134,515)	18,970,633,961	18,831,573,915	(158,074,469)
Import and Export Tax	-	184,242,555	268,417,611	(84,175,056)
Corporate income tax	51,446,027,518	49,136,958,425	62,465,383,416	38,117,602,527
+Payable	51,446,027,518	49,136,958,425	62,465,383,416	38,117,602,527
+Receivable	-	-	-	-
Personal income tax	1,124,787,936	11,070,192,471	9,241,325,169	2,953,655,238
+Payable	1,173,158,693	11,994,279,219	9,241,325,169	3,926,112,743
+Receivable	(48,370,757)	(924,086,748)	-	(972,457,505)
Land Tax	(4,554,998)	3,493,654,546	3,493,654,546	(4,554,998)
Others	494,545,893	1,397,113,551	1,839,696,099	51,963,345
+Payable	502,901,964	1,388,757,480	1,839,696,099	51,963,345
+Receivable	(8,356,071)	8,356,071	-	-
	53,169,318,177	86,320,291,174	98,293,794,370	41,195,814,981
In which:				
Receivable	(358,416,341)			(1,219,262,028)
Payable	53,527,734,518			42,415,077,009

20. OTHER CURRENT PAYABLES:

	As of September 30, 2026	As of December31, 2025
	VND	VND
Remuneration for Board of Directors, and Audit Committee	564,417,951	6,407,417,951
Thien Phuc Charity Fund	1,028,022,166	1,028,022,166
Others	773,976,719	845,357,854
	2,366,416,836	8,280,797,971

21. SHORT-TERM ACCRUED EXPENSES:

	As of September30, 2026	As of December31, 2025
	VND	VND
Selling expenses	10,865,828,476	24,773,459,652
Others	1,674,051,623	1,414,590,033
	12,539,880,099	26,188,049,685

22. LOANS:

	As of January 01, 2026	9 months of 2026		As of September 30, 2026
	VND	Increase VND	Decrease VND	VND
a,Short-term loan	43,214,775,628	249,466,404,668	138,011,669,581	154,669,510,715
Loan from banks	27,214,775,628	245,466,404,668	134,011,669,581	138,669,510,715
+ Bank for Investment and Development of Vietnam (BIDV), Binh Dinh Branch	14,268,551,500	221,799,339,616	97,398,380,401	138,669,510,715
+ Joint Stock Commercial Bank for Foreign Trade Of Vietnam, Binh Dinh Branch	12,946,224,128	23,667,065,052	36,613,289,180	-
Current portion	16,000,000,000	4,000,000,000	4,000,000,000	16,000,000,000
b,Non-current portion	132,000,000,000	120,358,587,357	12,000,000,000	240,358,587,357
Gia Lai Development Investment Fund	132,000,000,000	-	12,000,000,000	120,000,000,000
Bank for Agriculture and Rural Development of Vietnam, Binh Dinh Branch	-	120,358,587,357	-	120,358,587,357
	175,214,775,628	369,824,992,025	150,011,669,581	395,028,098,072

23. BONUS AND WELFARE FUNDS:

	Bonus fund	Welfare fund	Bonus fund for management	Total
	VND	VND	VND	VND
As of January 01,2026	49,017,924,602	73,230,409,537	5,862,924,302	128,111,258,441
Increase from profits	20,000,000	43,436,167	-	63,436,167
Other increase	14,040,000	7,800,000	-	21,840,000
Adjustment down (*)	(10,217,905,761)	(10,217,905,761)	-	(20,435,811,522)
Used funds	(2,215,840,000)	(3,268,418,514)	(5,851,200,000)	(11,335,458,514)
As of September 30, 2026	36,618,218,841	59,795,321,429	11,724,302	96,425,264,572

(*) Adjustment to reduce the amount provisionally appropriated to the Bonus fund and Welfare Funds for 2025 from 10% to 3% of the 2025 profit after tax, in accordance with Resolution No. 62/NQ-ĐHĐCĐ2026 dated April 25, 2026, as approved at the 2026 Annual General Meeting of Shareholders of Binh Dinh Pharmaceutical and Medical Equipment Joint Stock Company (Bidiphar).

24. SCIENTIFIC AND TECHNOLOGICAL DEVELOPMENT FUND:

	<i>Scientific and technological development fund</i>	<i>Scientific and technological development fund formed fixed assets</i>	<i>Total</i>
	VND	VND	VND
As of January 01,2026	115,949,061,957	16,821,268,119	132,770,330,076
Profit appropriation	-	-	-
Other Decrease	(10,959,801,541)	-	(10,959,801,541)
Depreciation charged to scientific and technological development fund	-	(2,099,416,996)	(2,099,416,996)
As of September 30, 2026	<u>104,989,260,416</u>	<u>14,721,851,123</u>	<u>119,711,111,539</u>

25. OWNER'S EQUITY:

	As of September 30, 2026			Beginning balance		
	Number of shares	Ownership %	Amount VND	Number of shares	Ownership %	Amount VND
GiaLaiDevelopment Investment Fund	12,485,606	13.21%	124,856,060,000	12,485,606	13.21%	124,856,060,000
KWE Beteiligungen AG	10,561,150	11.17%	105,611,500,000	10,053,550	10.64%	100,535,500,000
Others	71,442,506	75.58%	714,425,060,000	71,950,106	76.11%	719,501,060,000
Treasury shares	40,085	0.04%	400,850,000	40,085	0.04%	400,850,000
	<u>94,529,347</u>	<u>100%</u>	<u>945,293,470,000</u>	<u>94,529,347</u>	<u>100%</u>	<u>945,293,470,000</u>

26. OFF BALANCE SHEET ITEMS:

	As of September 30, 2026	As of December31, 2025
Foreign currencies:		
United States dollar (USD)	24,815.69	60,745.43
Euro (EUR)	<u>124.95</u>	<u>128.61</u>

27. REVENUE FROM GOODS SOLD AND SERVICES RENDERED:

	Third quarter of 2026	Third quarter of 2025	Accumulated nine months of 2026	Accumulated nine months of 2025
	VND	VND	VND	VND
Gross revenues	471,953,058,980	457,036,601,492	1,410,027,885,322	1,409,576,627,478
Of which:				
Sales of pharmaceutical finished goods	462,716,605,083	436,652,663,889	1,378,591,138,132	1,362,288,007,533
Sales of pharmaceutical merchandises	5,346,308,926	7,648,793,806	15,629,288,415	26,001,195,218
Sales of medical supplies	1,413,118,871	1,175,478,488	4,107,569,871	3,235,527,990
Sales of materials, packaging,tools and supplies	1,504,790,157	3,504,331,614	9,321,085,449	9,909,707,727
Others	972,235,943	8,055,333,695	2,378,803,455	8,142,189,010
Less	<u>11,866,963,100</u>	<u>17,338,229,305</u>	<u>30,188,493,342</u>	<u>54,296,185,249</u>
Trade discounts	10,259,344,256	15,946,421,299	26,341,437,211	51,418,944,031
Sales returns	1,607,618,844	1,391,808,006	3,847,056,131	2,877,241,218
Net	<u>460,086,095,880</u>	<u>439,698,372,187</u>	<u>1,379,839,391,980</u>	<u>1,355,280,442,229</u>

28. COST OF GOODS SOLD AND SERVICES RENDERED:

	Third quarter of 2026	Third quarter of 2025	Accumulated nine months of 2026	Accumulated nine months of 2025
	VND	VND	VND	VND
Cost of pharmaceutical finished goods sold	244,201,677,295	235,782,563,335	720,255,110,308	658,447,175,246
Cost of pharmaceutical merchandises sold	5,116,419,492	7,313,029,053	14,977,633,702	24,830,249,704
Cost of medical supplies sold	1,284,444,323	1,051,674,932	3,931,858,972	2,803,336,536
Cost of materials, packaging sold	360,670,752	2,525,538,287	1,732,011,904	5,525,832,482
Others	306,770,795	5,731,488,666	793,004,661	5,757,114,185
	251,269,982,657	252,404,294,273	741,689,619,547	697,363,708,153

29. PRODUCTION COST BY NATURE:

	Third quarter of 2026	Third quarter of 2025	Accumulated nine months of 2026	Accumulated nine months of 2025
	VND	VND	VND	VND
Raw materials and merchandise	154,857,916,269	136,160,787,930	545,126,798,915	444,003,997,809
Labor costs	101,014,053,642	54,215,497,467	300,465,169,811	261,213,574,083
Depreciation and amortization	10,059,911,106	12,836,872,293	29,767,247,137	37,658,957,705
External services expenses	39,840,280,314	38,592,962,108	116,000,412,084	110,506,482,216
Other expenses	36,326,610,540	60,315,853,937	121,575,305,577	139,597,324,697
Provision for doubtful debts	215,614,437	(1,100,054,529)	(520,746,900)	(3,736,706,861)
	342,314,386,308	301,021,919,206	1,112,414,186,624	989,243,629,649

30. FINANCIAL INCOME:

	Third quarter of 2026	Third quarter of 2025	Accumulated nine months of 2026	Accumulated nine months of 2025
	VND	VND	VND	VND
Interest income	9,601,532,244	5,153,756,712	26,624,763,547	13,636,885,818
Foreign exchange gains	268,391,535	3,934,319,774	1,208,161,060	4,659,354,855
	30,173,884,102	9,088,076,486	48,136,884,930	18,296,240,673

31. FINANCIAL EXPENSES:

	Third quarter of 2026	Third quarter of 2025	Accumulated nine months of 2026	Accumulated nine months of 2025
	VND	VND	VND	VND
Interest expenses	579,493,949	1,339,973,239	2,081,608,735	2,844,596,315
Payment discount	1,995,404,019	1,792,278,159	6,734,085,054	5,654,978,423
Foreign exchange loss	463,512,210	958,229,503	2,464,936,444	2,287,385,996
	3,038,410,178	4,090,480,901	11,280,630,233	10,786,960,734

32. SELLING EXPENSES:

	Third quarter of 2026	Third quarter of 2025	Accumulated nine months of 2026	Accumulated nine months of 2025
	VND	VND	VND	VND
Labor cost	51,239,834,554	26,084,573,493	156,912,422,215	153,145,497,670
Depreciation	970,592,452	756,136,526	2,676,351,715	2,360,111,780
External services expenses	12,186,200,242	16,655,992,214	37,339,740,910	45,038,763,872
Others	32,549,942,259	44,599,663,124	105,298,888,194	113,285,989,557
	96,946,569,507	88,096,365,357	302,227,403,034	313,830,362,879

33. GENERAL AND ADMINISTRATION EXPENSES:

	Third quarter of 2026	Third quarter of 2025	Accumulated nine months of 2026	Accumulated nine months of 2025
	VND	VND	VND	VND
Labor cost	15,095,107,653	3,140,915,751	44,323,062,803	38,283,871,402
Depreciation	572,436,183	2,173,293,577	1,786,846,813	6,767,526,686
External services expenses	4,814,825,402	4,510,940,538	13,604,956,887	12,367,414,245
Others	2,752,214,419	14,846,162,524	12,479,656,586	24,140,774,711
Provision for doubtful debts	215,614,437	(1,100,054,529)	(520,746,900)	(3,736,706,861)
	23,450,198,094	23,571,257,861	71,673,776,189	77,822,880,183

34. CORPORATE INCOME TAX EXPENSE:

	Third quarter of 2026	Third quarter of 2025	Accumulated nine months of 2026	Accumulated nine months of 2025
	VND	VND	VND	VND
Current corporate income tax expense	16,145,947,682	11,910,845,417	49,136,958,425	43,362,755,693
Deferred income tax income/ (expense)	751,711,246	(351,835,610)	1,646,238,290	(503,089,344)
	16,897,658,928	11,559,009,807	50,783,196,715	42,859,666,349

35. COMPARATIVE FIGURES:

Comparison data of some indicators have been re-presented to be appropriate according to TT99/2025/TT-BTC as of January 01,2026 and as of December 31,2025 (Beginning Balance):

CONSOLIDATED STATEMENT OF FINANCIAL POSITION

	Presented according to TT200		Adjusted according to TT99	
	Code	As of December 31, 2025	Code	As of December 31, 2025
1. ASSETS				
Short-term held-to-maturity investments (i)	123	409,200,000,000	123	413,595,057,535
Other short-term receivables (i)	136	8,933,170,440	135	4,538,112,905
Tangible fixed assets (ii)	221	271,987,287,244	221	272,520,459,520
- Cost (ii)	222	849,656,422,084	222	850,722,766,638
- Accumulated depreciation (ii)	223	(577,669,134,840)	223	(578,202,307,118)
Long-term deferred expenses (ii)	261	42,059,071,473	271	41,525,899,197
Long-term harvest crops (iii)		-	237	950,687,803
Costs of capital construction in progress (iii)	242	540,162,602,121	252	539,211,914,318
		1,272,342,131,278		1,272,342,131,278
2. RESOURCES				
Dividends payables (ii)		-	313	1,600,459,750
Other short-term payables (ii)	319	9,881,257,721	320	8,280,797,971
Other capital (iii)	414	-	414	2,242,183,741
Non-business expenditure fund and other funds (iii)	430	2,242,183,741		-
Non-business expenditure fund (iii)	431	719,369,206		-
Non-business expenditure fund invested in fixed assets (iii)	432	1,522,814,535		-
		12,123,441,462		12,123,441,462

(i) Interest income receivables from term-deposits at banks were reclassified from other short-term receivables to short-term held-to-maturity investments.

(ii) Bearer plants were reclassified from long-term deferred expenses to tangible fixed assets.

(iii) Plants producing one-time products that are expected to be harvested after more than 12 months were reclassified from construction in progress to seasonal crops or plants producing one-time products – long-term.

(iv) Dividends payable were reclassified from other short term payables to dividends payable, a separate code on the consolidated statement of financial position.

(v) Non-business expenditure fund and other funds, a separate code on the consolidated statement of financial position, were reclassified to other capital.


Le Thi Kieu My
Preparer


Do Huy Phuong
Chief Accountant


Pham Thi Thanh Huong
General Director
October 26, 2026

